The NIH clinical trial is a significant milestone for GM1 gangliosidosis, a deadly disease with no approved treatment. The clinical trial treatment was originated and created at Auburn University’s ...
"Vuelta alto, mi princesa". Con esta frase escrita en blanco sobre fondo negro se despertaban este martes por la mañana los ...
Sanofi is still running studies of the glycosphingolipid (GSL) inhibitor in rare lysosomal storage diseases like Gaucher disease type 3, Fabry disease and GM2 gangliosidosis (also known as Tay ...
The accumulation of GM1 ganglioside that occurs in the lysosomal storage disorder GM1 gangliosidosis may cause neurodegeneration through dysregulation of intracellular calcium and subsequent induction ...
Company’s lead asset, nizubaglustat, awarded GM1 Orphan Drug Designation by the US Food and Drug administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency (EMA) ...
Acetylleucine (IB-1001) is under development for the treatment of Niemann-Pick disease type C, GM1 Gangliosidosis, GM2 gangliosidosis, ataxia telangiectasia, spinocerebellar ataxia, Tay-Sachs Disease, ...
Acetylleucine (IB-1001) is under development for the treatment of Niemann-Pick disease type C, GM1 Gangliosidosis, GM2 gangliosidosis, ataxia telangiectasia, spinocerebellar ataxia, Tay-Sachs Disease, ...
Vega Gómez, la pequeña zaragozana, de 3 años de edad, diagnosticada con Gangliosidosis GM1 infantil, ha fallecido en Zaragoza, según se recoge en el perfil Todos Con Vega, creado por sus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback